Bayer HealthCare AG, a subsidiary of Bayer AG, Headquartered in Leverkusen, Germany, Bayer HealthCare plays a major role in improving the health of people and animals by researching, developing, manufacturing and marketing innovative products for disease prevention, diagnosis and treatment.
The company combines the global activities of the divisions Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. Bayer HealthCare generated sales amounting to some 94 billion Euro in 2005.
A significant milestone is the acquisition of Roche Consumer Health on January 1st, 2005. Consumer Care is among the first three leading OTC suppliers of the world.Its Pharmaceutical Division's prescription drugs business plays a central role, focusing primary care business in cardiovascular risk management, infectious diseases, and urology, and accelerating strategic growth in the Specialty areas, such as oncology.
Since 1990s Bayer HealthCare started fast business development in China. In 1995 Bayer HealthCare started to build manufacture factory, and in 1997 the drug production started operation.
Currently Bayer HealthCare in China has two joint venture companies, namely Bayer HealthCare Co., Ltd. and Bayer (Sichuan) Animal Health Co., Ltd.Bayer HealthCare in China is presented by four businesses: pharmaceuticals, consumer care, diagnostics and animal health.
Bayer HealthCare China PH division has 6 sales regions and 12 sales offices.The business covers 70 cities in China. The company is to develop, manufacture and market products in the fields of cardiovascular diseases, anti infections, diabetes and urology . Milestones for 2006 include the expected market launch of Nexavar in the United States and Europe for the treatment of advanced kidney cancer and continuing systematic development of the active ingredient for use in liver cancer and melanoma.
Bayer HealthCare Plant locates at Beijing Development Area, and occupies 36,000 square meters. The BHC factory is one of the initiators in China to implement GMP regulations.Solid and semi-solid pharmaceuticals can be manufactured here. The state-of-the-art plant fulfills international GMP standards.
In addition, packaging of parenteral products is done here, all in all 15 production lines, 13 of them for production or packaging, 2 to finish imported goods. In addition to meet China market demands, the products also exported to Japan. |
